Role of TGFbeta Ligand Function in the Development and Pathogenesis of Cardiovascular Disease
A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Basic and Translational Cardiovascular Research".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 2596
Special Issue Editors
Interests: transforming growth factor; cardiovascular development; valve development; valvular heart disease; aortic aneurysm; aortic calcification
Special Issues, Collections and Topics in MDPI journals
Interests: abdominal aortic aneurysm
Interests: aortic valve; heart valve diseases; vascular surgery; aneurysm cardiac surgery; aortic diseases; atherosclerotic vascular diseases; cardiovascular surgery; coronary artery bypass surgery; endovascular surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We welcome review and original article contributions that increase our understanding of the transforming growth factor beta (TGFB) pathway in cardiovascular development and disease. TGFB ligands (TGFB1,2,3) are multifunctional growth factors and cytokines that are produced in latent form by most cardiac cell types during cardiovascular development and in adult cardiovascular tissues. All TGFB ligands bind to the TGFBR1 and TGFBR2 receptor complex. Downstream signaling occurs through phosphorylation and nuclear translocation of SMAD2 and SMAD3 in conjunction with SMAD4. In addition, the TGFB ligand–receptor complex also activates non-canonical pathways involving the MAP kinase pathway (TAK, p38, ERK1/2 MAPK). TGFB-regulated gene expression controls cell differentiation, cell growth, apoptosis, cell migration, and extracellular matrix production and remodeling during cardiovascular development and pathogenesis of cardiovascular disease. Genetic mutations in TGFB2 and TGFB3 cause congenital heart disease, bicuspid aortic valve, mitral valve disease, and aortic aneurysm and dissection in patients of Loeys–Dietz syndrome. Increased TGFB1 expression is associated with cardiomyopathy, mitral valve prolapse, and aortic aneurysm in Marfan syndrome. Increased TGFB signaling is found in cardiac fibrosis, cardiac hypertrophy, myocardial infarction and heart failure, hypertension, atherosclerosis, arterial calcification, and thoracic and abdominal aortic aneurysms. Thus, understanding the cell-specific role and molecular and biochemical mechanisms of TGFβ ligands will lead to safer and more effective therapy for cardiovascular disease. Consequently, we invite author contributions that advance our current understanding of TGFβ signaling in cardiovascular development and cardiovascular disease. We suggest the following themes for this Special Issue:
- TGFβ in cardiovascular development;
- TGFβ in aortopathy: thoracic and abdominal aneurysm, arterial calcification, atherosclerosis;
- TGFβ in bicuspid aortic valve, mitral valve disease, aortic valve calcification, aortic stenosis;
- TGFβ in cardiac hypertrophy, cardiac fibrosis, heart failure;
- TGFβ in hypertension and atherosclerosis;
- TGFβ signaling mechanism using in vitro cell and tissue culture models;
- Novel models of TGFβ signaling in the cardiovascular system;
TGFβ-based therapies of cardiovascular disease and cardiotoxicity.
Dr. Mohamad Azhar
Dr. Chetan Hans
Dr. Nimrat Grewal
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- transforming growth factor beta
- TGFB1
- TGFB2
- TGFB3
- aortic valve
- aneurysm
- mitral valve
- congenital heart disease
- fibrosis
- hypertrophy
- hypertension
- atherosclerosis
- peripheral artery disease
- heart failure
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
